ROCKET trial

URI: https://gptkb.org/entity/ROCKET_trial
GPTKB entity
Statements (24)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:abbreviation gptkb:ROCKET_AF
gptkbp:clinicalTrialPhase gptkb:NCT00403767
gptkbp:comparatorDrug gptkb:warfarin
gptkbp:conditionStudied gptkb:atrial_fibrillation
gptkbp:country multinational
gptkbp:fullName gptkb:Rivaroxaban_Once_Daily_Oral_Direct_Factor_Xa_Inhibition_Compared_with_Vitamin_K_Antagonism_for_Prevention_of_Stroke_and_Embolism_Trial_in_Atrial_Fibrillation
https://www.w3.org/2000/01/rdf-schema#label ROCKET trial
gptkbp:participants 14,264
gptkbp:period Phase III
gptkbp:principalInvestigator gptkb:Manesh_R._Patel
gptkbp:publicationYear 2011
gptkbp:publishedIn gptkb:New_England_Journal_of_Medicine
gptkbp:result prevention of stroke and systemic embolism
rivaroxaban was non-inferior to warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
gptkbp:sponsor gptkb:Bayer_Healthcare
gptkb:Johnson_&_Johnson
gptkbp:startYear 2006
gptkbp:studiedDrug gptkb:rivaroxaban
gptkbp:studyType event-driven
double-blind
randomized
gptkbp:bfsParent gptkb:JCAR015
gptkbp:bfsLayer 6